New triple therapy takes on pancreatic cancer

NCT ID NCT06767813

Recruiting now Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 2 trial is testing whether adding an experimental immunotherapy (TQB2868) and a targeted drug (anlotinib) to standard chemotherapy can help people with pancreatic cancer that has spread. The study will enroll 80 adults who have not had prior treatment. Researchers will measure how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB2868 injection (a bifunctional fusion protein targeting PD-1 and TGF-βRII), anlotinib capsules, gemcitabine injection, and albumin paclitaxel injection
What this could lead to: If successful, this combination could offer a new first-line treatment option for pancreatic cancer, potentially improving how long patients live without their cancer growing.
What could go wrong: This is an early Phase 2 trial with only 80 participants, so results may not apply to all patients. The combination also carries risks of side effects from chemotherapy and the immune-targeting drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC NEOPLASMS

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
Jiangsu Provincial People's Hospital
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210000, China
Nanjing Drum Tower Hospital
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210000, China
The First Affiliated Hospital of Soochow University
NOT_YET_RECRUITING

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITING

Wenzhou, Zhejiang, 325000, China
The Second Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITING

Zhengzhou, Henan, 450039, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.